Current perspectives on the use of eplerenone for chronic central serous chorioretinopathy

Eye (Lond). 2021 Dec;35(12):3445-3447. doi: 10.1038/s41433-020-01325-9. Epub 2020 Nov 30.

Authors

Yonghui Xia¹, Rui Hua^{2

3}

Affiliations

¹ Department of Radiology, First Hospital of China Medical University, Shenyang, China.
² Department of Ophthalmology, First Hospital of China Medical University, Shenyang, China. woodshua@126.com.
³ Macular Disease Research Laboratory, Department of Ophthalmology, West China Hospital, Sichuan University, Chengdu, China. woodshua@126.com.

No abstract available

Publication types

Letter
Comment

MeSH terms

Central Serous Chorioretinopathy* / diagnosis
Central Serous Chorioretinopathy* / drug therapy
Eplerenone / therapeutic use
Fluorescein Angiography
Humans
Mineralocorticoid Receptor Antagonists / therapeutic use

Substances

Mineralocorticoid Receptor Antagonists
Eplerenone